Your browser doesn't support javascript.
loading
Rodent Models of Retinal Degeneration: From Purified Cells in Culture to Living Animals.
Fradot, Valérie; Augustin, Sébastien; Fontaine, Valérie; Marazova, Katia; Guillonneau, Xavier; Sahel, José A; Picaud, Serge.
Afiliação
  • Fradot V; Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris F-75012, France.
  • Augustin S; Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris F-75012, France.
  • Fontaine V; Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris F-75012, France.
  • Marazova K; Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris F-75012, France.
  • Guillonneau X; Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris F-75012, France.
  • Sahel JA; Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris F-75012, France.
  • Picaud S; Department of Ophthalmology, The University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
Article em En | MEDLINE | ID: mdl-37848250
ABSTRACT
Rodent models of retinal degeneration are essential for the development of therapeutic strategies. In addition to living animal models, we here also discuss models based on rodent cell cultures, such as purified retinal ganglion cells and retinal explants. These ex vivo models extend the possibilities for investigating pathological mechanisms and assessing the neuroprotective effect of pharmacological agents by eliminating questions on drug pharmacokinetics and bioavailability. The number of living rodent models has greatly increased with the possibilities to achieve transgenic modifications in animals for knocking in and out genes and mutations. The Cre-lox system has further enabled investigators to target specific genes or mutations in specific cells at specific stages. However, chemically or physically induced models can provide alternatives to such targeted gene modifications. The increased diversity of rodent models has widened our possibility to address most ocular pathologies for providing initial proof of concept of innovative therapeutic strategies.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article